Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have been given an average rating of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $15.00.

Several equities research analysts recently weighed in on the stock. Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. William Blair assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, April 21st.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Ally Bridge Group NY LLC acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $5,398,000. Quadrature Capital Ltd acquired a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at about $326,000. Bank of America Corp DE lifted its holdings in Eupraxia Pharmaceuticals by 262.9% in the 3rd quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock valued at $269,000 after acquiring an additional 33,018 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in Eupraxia Pharmaceuticals by 173.3% in the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock valued at $197,000 after acquiring an additional 21,161 shares during the last quarter. Finally, Aptus Capital Advisors LLC acquired a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000.

Eupraxia Pharmaceuticals Stock Performance

EPRX stock opened at $6.29 on Wednesday. The company has a market capitalization of $380.10 million, a P/E ratio of -5.99 and a beta of 1.19. The company has a 50-day simple moving average of $7.23 and a 200 day simple moving average of $7.31. Eupraxia Pharmaceuticals has a fifty-two week low of $3.67 and a fifty-two week high of $9.32. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.